

For immediate release: 15 April 2014

Kromek Group plc (“Kromek” or “the Company”)

Director / PDMR shareholding

The Company was informed on 14 April 2014 that Lawrence Kinet, Director of the Company, purchased 30,000 Ordinary Shares ("Shares") of 1p each at an average of 46p per share on 14 April 2014, representing approximately 0.028% of the Company's total issued share capital.

Mr Kinet's total holding in the Company is now 30,000 Shares of 1p each, representing approximately 0.028% of the Company's total issued share capital.

-ends-

For further information, please contact:

Kromek Group plc

Arnab Basu, CEO
Derek Bulmer, CFO

Tel: 01740 626060

Panmure Gordon

As Nominated Adviser and Broker
Corporate Finance
Freddy Crossley
Broking

Tel: 020 7886 2500

Adam Pollock/ Charles Leigh-Pemberton

Tavistock Communications

Matt Ridsdale / Andrew Dunn

Tel: 020 7920 3150

About Kromek Group plc

Kromek Group plc is a UK technology company (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT"). Using its core CZT technology Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

Kromek uses multiple technologies in its manufacturing processes, including the established methods of 'liquid phase' detector production, and also 'vapour phase' production methods, which allow the production of high quality, high performance detectors on an industrial scale. Kromek has an intellectual property portfolio of more than 70 granted patents and 110 pending applications.

The Group's business model provides a vertically integrated technology offering to customers, from the growth of CZT crystals to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").

The Board believes that the vertical integration offered by Kromek, combined with the benefit of 25 years of research into CZT production and the patents and trade secrets accumulated by the Group, are unparalleled in the market place.

The Group has operations in the UK, Germany and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

Currently, the Group has over a hundred full time employees across its global operations.